Pulmonx Q3 2024 GAAP EPS $(0.36) Beats $(0.45) Estimate, Sales $20.387M Beat $20.288M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pulmonx (NASDAQ:LUNG) reported better-than-expected Q3 2024 results with a GAAP EPS of $(0.36), beating the estimate of $(0.45). Sales reached $20.387M, surpassing the $20.288M estimate and marking a 15.39% increase from the previous year.
October 30, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulmonx reported Q3 2024 results that exceeded expectations, with a GAAP EPS of $(0.36) beating the $(0.45) estimate and sales of $20.387M surpassing the $20.288M estimate. This indicates strong performance and growth, with sales increasing by 15.39% year-over-year.
Pulmonx's better-than-expected earnings and sales figures suggest positive market sentiment and potential stock price appreciation. The 15.39% YoY sales growth further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100